Myst Therapeutics

Los Angeles, United States Founded: 2019 • Age: 7 yrs Acquired By Turnstone Biologics
Developer of cell therapy for treating cancer

About Myst Therapeutics

Myst Therapeutics is a Healthcare company based in Los Angeles (United States) founded in 2019, and was acquired by Turnstone Biologics in January 2021. Developer of cell therapy for treating cancer. Its chief executive, as recorded, is Timothy Langer. Its focus areas include Life Sciences, Cell Therapy, Adoptive Cell Therapy and T-Cell. Its competitors include Poseida Therapeutics, Juno Therapeutics and TScan Therapeutics; 3 of its 3 listed competitors have raised funding.

Company details

Myst Therapeutics was founded in 2019 and is based in Los Angeles, United States. Operations focus on the biotechnology sector, specifically adoptive cell therapy for oncology. T cells sourced from tumors and peripheral blood are utilized to target a wide range of cancer mutations. Development efforts center on advancing this therapy through clinical and preclinical stages.

  • Headquarters Los Angeles, United States
  • Stage Acquired
  • Sectors
    Healthcare
  • Phone
    β€’β€’β€’β€’ β€’β€’β€’β€’
  • Website myst-tx.com
  • Social LinkedIn
  • Acquired by Turnstone Biologics (Jan 2021)
Key Metrics

Investors in Myst Therapeutics

Myst Therapeutics has secured backing from 1 investor. Prominent investors backing the company include XOMA Royalty.

All
InvestorDescriptionFounded YearDomainLocation
XOMA Royalty is engaged in biotech royalty aggregation activities.
2015turnstonebio.comSan Diego, United States
Premium access

Investor details for Myst Therapeutics

The complete investor list, round-by-round participation and investor portfolios require an active premium plan.

  • Complete investor list
  • Round participation
  • Investor portfolios
  • Co-investor network

Verified entity values are shown only after access is granted.

People of Myst Therapeutics

1 people are tracked at Myst Therapeutics (1 in leadership).

NameRoleGroup
Timothy Langer
CEOLeadership
Premium access

Complete people profiles for Myst Therapeutics

Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.

  • Full employee list
  • Team structure
  • Board tenure
  • Professional contacts

Verified entity values are shown only after access is granted.

Timeline of Myst Therapeutics

2 dated milestones of Myst Therapeutics across 2 years, from founding to its latest funding, stage changes and deals.

  1. Founded Myst Therapeutics is founded.
  2. Exit Acquired by Turnstone Biologics.

Competitors of Myst Therapeutics

Myst Therapeutics has 3 listed competitors in our database, 3 of them funded. They include Poseida Therapeutics, Juno Therapeutics and TScan Therapeutics.

Company NameDomainFoundedHQ LocationTotal fundingEmployeesDescription
poseida.com2015San Diego, United States$323.78M259
Developer of gene therapies for treating cancer and liver orphan disease by using gene editing technologies
junotherapeutics.com2013Seattle, United States$316.67M520
CAR T-cell and T-cell receptor immunotherapies for cancer are developed.
tscan.com1995Boston, United States$158.3M154
T cell-based treatments for immunological and oncological disorders are developed.
Premium access

Detailed competitors of Myst Therapeutics

The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.

  • Full competitor set
  • Operating metrics
  • Benchmarks
  • Competitive positioning

Verified entity values are shown only after access is granted.

Top companies in Cell Therapy

3 companies that operate in the same segment as Myst Therapeutics (Cell Therapy) in United States, ranked by their profile score on The Company Check.

CompanyDescriptionFoundedLocationTotal fundingRevenueEmployees
CAR T-cell and T-cell receptor immunotherapies for cancer are developed.
2013Seattle, Washington, United StatesUSD 316.67 M520
CAR-T and TIL immunotherapies for solid tumors are developed.
2018San Francisco, California, United StatesUSD 493 MUSD 36 K233
Smart surgical devices for spinal surgery are developed.
1997San Diego, California, United StatesUSD 54.1 M
Upgrade to premium

Unlock complete access to The Company Check

Get unrestricted viewing across everything we track β€” from companies and brands to investors, funding rounds, acquisitions, financials, and more.

Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.
Included in your Premium account
  • βœ“
    Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
  • βœ“
    Full access to every database India & global coverage, advanced filters and rich profile details
  • βœ“
    Always-on access from your team account Single premium plan for everything you see on the portal

Related news about Myst Therapeutics

Premium access

Complete news archive for Myst Therapeutics

Full article history, source details, and older brand coverage require an active premium plan.

  • Full article archive
  • Source and publication date
  • Older coverage
  • Brand-specific news history

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Myst Therapeutics

Myst Therapeutics was founded in 2019.

Myst Therapeutics is headquartered in Los Angeles, United States. It is registered at Los Angeles, California, United States.

Timothy Langer is the CEO of Myst Therapeutics, as recorded in our data.

Myst Therapeutics was founded in 2019 and is based in Los Angeles, United States. Operations focus on the biotechnology sector, specifically adoptive cell therapy for oncology. T cells sourced from tumors and peripheral blood are utilized to target a wide range of cancer mutations. Development efforts center on advancing this therapy through clinical and preclinical stages.

Myst Therapeutics's top competitors include Juno Therapeutics, Poseida Therapeutics and TScan Therapeutics.

Myst Therapeutics has 1 investor. Key investors include XOMA Royalty.

Yes. Myst Therapeutics was acquired by Turnstone Biologics in January 2021.

Explore millions of companies β€” effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals β€” all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available